Maze Therapeutics (MAZE) Other financing activities (2024 - 2026)

Maze Therapeutics has reported Other financing activities for 3 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Other financing activities fell 96.81% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 96.82% YoY) and the FY2025 annual result came in at $127.8 million, up 17328.65% from the prior year.
• Other financing activities grew to $4.1 million in Q1 2026 per MAZE's latest filing, from -$14.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $127.8 million in Q1 2025 and troughed at -$14.0 million in Q4 2025.
• A 3-year average of $16.6 million and a median of $295500.0 in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 34900.55% in 2025, down 22315.87% in 2025.
• Over 3 years, Other financing activities stood at $63000.0 in 2024, then sank by 22315.87% to -$14.0 million in 2025, then soared by 129.14% to $4.1 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $4.1 million, -$14.0 million, and $14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.